September 30, 2026

@michaelokun

Bravo on the recent reauthorization of ACT for ALS. This bill was critically important because federal programs were set to expire, threatening momentum in expanded access to investigational therapies and ALS research. The ACT for ALS Reauthorization Act of 2026 extends programs that help people with ALS who may not qualify for traditional clinical trials access promising experimental therapies, while simultaneously collecting data that can move the entire field forward. For a rapidly progressive and fatal disease like ALS, time matters. We need rigorous science, but we must pair that rigor with urgency, access, and hope. Reauthorizing ACT for ALS keeps that critical pathway moving forward. Additionally, the Healey ALS platform has been more quickly identifying and testing the most promising ALS therapies. https://onlinelibrary.wiley.com/doi/10.1002/ana.26285?utm_medium=article&utm_source=researchgate.net